IL175063A - Use of pif peptides in the manufacture of a medicament for treating intolerance to embryo implantation - Google Patents

Use of pif peptides in the manufacture of a medicament for treating intolerance to embryo implantation

Info

Publication number: IL175063A
Authority: IL; Israel
Prior art keywords: pif; seq; peptide; peptides; embryo
Prior art date: 2003-10-22

Application number

IL175063A

Other languages

English (en)

Other versions

IL175063A0 (en

Original Assignee

Bioincept Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-22

Filing date

2006-04-20

Publication date

2011-10-31

2006-04-20 Application filed by Bioincept Inc filed Critical Bioincept Inc

2006-08-20 Publication of IL175063A0 publication Critical patent/IL175063A0/en

2011-10-31 Publication of IL175063A publication Critical patent/IL175063A/en

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims description 118
102000004196 processed proteins & peptides Human genes 0.000 title claims description 43
239000003814 drug Substances 0.000 title claims description 18
230000032692 embryo implantation Effects 0.000 title claims description 7
238000004519 manufacturing process Methods 0.000 title claims description 6
GLXYOFXNKBTMQL-YKCHQESGSA-N (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-methylbutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]butanedioic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O)CCC1 GLXYOFXNKBTMQL-YKCHQESGSA-N 0.000 claims description 182
102000004127 Cytokines Human genes 0.000 claims description 39
108090000695 Cytokines Proteins 0.000 claims description 39
230000002357 endometrial effect Effects 0.000 claims description 15
102000008607 Integrin beta3 Human genes 0.000 claims description 8
108010020950 Integrin beta3 Proteins 0.000 claims description 8
230000036039 immunity Effects 0.000 claims description 7
230000000694 effects Effects 0.000 description 65
210000001161 mammalian embryo Anatomy 0.000 description 65
230000035935 pregnancy Effects 0.000 description 59
108010022347 proteolysis-inducing peptide Proteins 0.000 description 56
210000004027 cell Anatomy 0.000 description 48
241000282414 Homo sapiens Species 0.000 description 46
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 46
230000008774 maternal effect Effects 0.000 description 41
238000000034 method Methods 0.000 description 41
108090000623 proteins and genes Proteins 0.000 description 40
230000027455 binding Effects 0.000 description 35
102000004169 proteins and genes Human genes 0.000 description 30
210000004698 lymphocyte Anatomy 0.000 description 29
150000001875 compounds Chemical class 0.000 description 27
102000005962 receptors Human genes 0.000 description 26
108020003175 receptors Proteins 0.000 description 26
238000003556 assay Methods 0.000 description 24
238000002513 implantation Methods 0.000 description 22
201000004792 malaria Diseases 0.000 description 21
210000002966 serum Anatomy 0.000 description 21
210000000987 immune system Anatomy 0.000 description 20
210000002826 placenta Anatomy 0.000 description 20
241000699670 Mus sp. Species 0.000 description 19
108010047620 Phytohemagglutinins Proteins 0.000 description 19
125000003275 alpha amino acid group Chemical group 0.000 description 19
230000001885 phytohemagglutinin Effects 0.000 description 19
210000001519 tissue Anatomy 0.000 description 19
210000002865 immune cell Anatomy 0.000 description 18
239000000816 peptidomimetic Substances 0.000 description 18
108010042412 prolactin-inhibitory factor receptor Proteins 0.000 description 17
230000007423 decrease Effects 0.000 description 16
230000004720 fertilization Effects 0.000 description 16
238000002965 ELISA Methods 0.000 description 15
210000002459 blastocyst Anatomy 0.000 description 15
238000000684 flow cytometry Methods 0.000 description 15
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 14
210000001744 T-lymphocyte Anatomy 0.000 description 14
210000002257 embryonic structure Anatomy 0.000 description 14
230000035755 proliferation Effects 0.000 description 14
108090000174 Interleukin-10 Proteins 0.000 description 13
102000003814 Interleukin-10 Human genes 0.000 description 13
210000003754 fetus Anatomy 0.000 description 13
239000001963 growth medium Substances 0.000 description 13
210000001616 monocyte Anatomy 0.000 description 13
230000028327 secretion Effects 0.000 description 13
102100026992 Dermcidin Human genes 0.000 description 12
241000124008 Mammalia Species 0.000 description 12
239000000427 antigen Substances 0.000 description 12
102000036639 antigens Human genes 0.000 description 11
108091007433 antigens Proteins 0.000 description 11
230000000670 limiting effect Effects 0.000 description 11
239000012071 phase Substances 0.000 description 11
241000283973 Oryctolagus cuniculus Species 0.000 description 10
150000001413 amino acids Chemical class 0.000 description 10
238000011161 development Methods 0.000 description 10
230000018109 developmental process Effects 0.000 description 10
210000002443 helper t lymphocyte Anatomy 0.000 description 10
230000001965 increasing effect Effects 0.000 description 10
239000003226 mitogen Substances 0.000 description 10
239000000203 mixture Substances 0.000 description 10
238000012360 testing method Methods 0.000 description 10
101710117490 Circumsporozoite protein Proteins 0.000 description 9
241001465754 Metazoa Species 0.000 description 9
241000699666 Mus <mouse, genus> Species 0.000 description 9
102100030569 Nuclear receptor corepressor 2 Human genes 0.000 description 9
101710153660 Nuclear receptor corepressor 2 Proteins 0.000 description 9
150000001408 amides Chemical class 0.000 description 9
230000004071 biological effect Effects 0.000 description 9
229960002685 biotin Drugs 0.000 description 9
239000011616 biotin Substances 0.000 description 9
238000010790 dilution Methods 0.000 description 9
239000012895 dilution Substances 0.000 description 9
241000282412 Homo Species 0.000 description 8
102100025237 T-cell surface antigen CD2 Human genes 0.000 description 8
239000005557 antagonist Substances 0.000 description 8
210000003719 b-lymphocyte Anatomy 0.000 description 8
238000004166 bioassay Methods 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 8
235000013601 eggs Nutrition 0.000 description 8
239000003550 marker Substances 0.000 description 8
239000002609 medium Substances 0.000 description 8
238000010186 staining Methods 0.000 description 8
238000012546 transfer Methods 0.000 description 8
238000011282 treatment Methods 0.000 description 8
210000002993 trophoblast Anatomy 0.000 description 8
230000035899 viability Effects 0.000 description 8
230000004913 activation Effects 0.000 description 7
235000020958 biotin Nutrition 0.000 description 7
230000002254 contraceptive effect Effects 0.000 description 7
210000004696 endometrium Anatomy 0.000 description 7
239000012530 fluid Substances 0.000 description 7
238000000338 in vitro Methods 0.000 description 7
238000007799 mixed lymphocyte reaction assay Methods 0.000 description 7
230000003169 placental effect Effects 0.000 description 7
241000894007 species Species 0.000 description 7
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
108010074328 Interferon-gamma Proteins 0.000 description 6
108010002350 Interleukin-2 Proteins 0.000 description 6
102000000588 Interleukin-2 Human genes 0.000 description 6
108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
102100040247 Tumor necrosis factor Human genes 0.000 description 6
125000000217 alkyl group Chemical group 0.000 description 6
230000008859 change Effects 0.000 description 6
229940079593 drug Drugs 0.000 description 6
-1 hydroxy, carboxy Chemical group 0.000 description 6
230000028993 immune response Effects 0.000 description 6
230000003993 interaction Effects 0.000 description 6
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
102000004217 thyroid hormone receptors Human genes 0.000 description 6
108090000721 thyroid hormone receptors Proteins 0.000 description 6
238000001262 western blot Methods 0.000 description 6
241000826760 Barnea Species 0.000 description 5
102100021277 Beta-secretase 2 Human genes 0.000 description 5
241000283690 Bos taurus Species 0.000 description 5
241000283707 Capra Species 0.000 description 5
102000004388 Interleukin-4 Human genes 0.000 description 5
108090000978 Interleukin-4 Proteins 0.000 description 5
PDIDTSZKKFEDMB-UWVGGRQHSA-N Lys-Pro-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O PDIDTSZKKFEDMB-UWVGGRQHSA-N 0.000 description 5
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
231100000673 dose–response relationship Toxicity 0.000 description 5
230000002349 favourable effect Effects 0.000 description 5
239000012091 fetal bovine serum Substances 0.000 description 5
108010082286 glycyl-seryl-alanine Proteins 0.000 description 5
230000012010 growth Effects 0.000 description 5
230000002519 immonomodulatory effect Effects 0.000 description 5
230000008105 immune reaction Effects 0.000 description 5
239000007943 implant Substances 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
102000006495 integrins Human genes 0.000 description 5
108010044426 integrins Proteins 0.000 description 5
238000002955 isolation Methods 0.000 description 5
210000002540 macrophage Anatomy 0.000 description 5
239000012528 membrane Substances 0.000 description 5
208000000995 spontaneous abortion Diseases 0.000 description 5
210000004291 uterus Anatomy 0.000 description 5
206010000234 Abortion spontaneous Diseases 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 4
101100244725 Caenorhabditis elegans pef-1 gene Proteins 0.000 description 4
102100037850 Interferon gamma Human genes 0.000 description 4
208000006399 Premature Obstetric Labor Diseases 0.000 description 4
206010036600 Premature labour Diseases 0.000 description 4
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 4
241000282898 Sus scrofa Species 0.000 description 4
YSGAPESOXHFTQY-IHRRRGAJSA-N Tyr-Met-Asp Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N YSGAPESOXHFTQY-IHRRRGAJSA-N 0.000 description 4
108010040443 aspartyl-aspartic acid Proteins 0.000 description 4
239000013060 biological fluid Substances 0.000 description 4
210000005168 endometrial cell Anatomy 0.000 description 4
230000001605 fetal effect Effects 0.000 description 4
230000006870 function Effects 0.000 description 4
238000004128 high performance liquid chromatography Methods 0.000 description 4
230000001939 inductive effect Effects 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
208000015994 miscarriage Diseases 0.000 description 4
210000000822 natural killer cell Anatomy 0.000 description 4
231100000252 nontoxic Toxicity 0.000 description 4
210000000056 organ Anatomy 0.000 description 4
244000045947 parasite Species 0.000 description 4
208000026440 premature labor Diseases 0.000 description 4
230000008569 process Effects 0.000 description 4
150000004492 retinoid derivatives Chemical class 0.000 description 4
230000001960 triggered effect Effects 0.000 description 4
101710150190 Beta-secretase 2 Proteins 0.000 description 3
241000283073 Equus caballus Species 0.000 description 3
241000156978 Erebia Species 0.000 description 3
VXQOONWNIWFOCS-HGNGGELXSA-N Glu-His-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CCC(=O)O)N VXQOONWNIWFOCS-HGNGGELXSA-N 0.000 description 3
102100034343 Integrase Human genes 0.000 description 3
YTJFXEDRUOQGSP-DCAQKATOSA-N Lys-Pro-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O YTJFXEDRUOQGSP-DCAQKATOSA-N 0.000 description 3
ALTHVGNGGZZSAC-SRVKXCTJSA-N Met-Val-Arg Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCNC(N)=N ALTHVGNGGZZSAC-SRVKXCTJSA-N 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
241001494479 Pecora Species 0.000 description 3
102000001708 Protein Isoforms Human genes 0.000 description 3
108010029485 Protein Isoforms Proteins 0.000 description 3
MWMKFWJYRRGXOR-ZLUOBGJFSA-N Ser-Ala-Asn Chemical compound N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)CC(N)=O)C)CO MWMKFWJYRRGXOR-ZLUOBGJFSA-N 0.000 description 3
210000000612 antigen-presenting cell Anatomy 0.000 description 3
230000008901 benefit Effects 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
230000004663 cell proliferation Effects 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
239000003636 conditioned culture medium Substances 0.000 description 3
239000003433 contraceptive agent Substances 0.000 description 3
210000001771 cumulus cell Anatomy 0.000 description 3
238000002405 diagnostic procedure Methods 0.000 description 3
210000002919 epithelial cell Anatomy 0.000 description 3
230000012173 estrus Effects 0.000 description 3
210000004408 hybridoma Anatomy 0.000 description 3
230000008629 immune suppression Effects 0.000 description 3
208000026278 immune system disease Diseases 0.000 description 3
230000006058 immune tolerance Effects 0.000 description 3
230000006028 immune-suppresssive effect Effects 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
230000000977 initiatory effect Effects 0.000 description 3
238000004949 mass spectrometry Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
230000013011 mating Effects 0.000 description 3
239000013642 negative control Substances 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
210000003101 oviduct Anatomy 0.000 description 3
239000006187 pill Substances 0.000 description 3
210000005059 placental tissue Anatomy 0.000 description 3
230000000270 postfertilization Effects 0.000 description 3
239000002243 precursor Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
239000000047 product Substances 0.000 description 3
230000000770 proinflammatory effect Effects 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
230000000284 resting effect Effects 0.000 description 3
239000000523 sample Substances 0.000 description 3
238000012216 screening Methods 0.000 description 3
238000013207 serial dilution Methods 0.000 description 3
230000011664 signaling Effects 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000000243 solution Substances 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
239000000126 substance Substances 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
230000003558 thrombophilic effect Effects 0.000 description 3
230000036962 time dependent Effects 0.000 description 3
210000004340 zona pellucida Anatomy 0.000 description 3
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
102100024341 10 kDa heat shock protein, mitochondrial Human genes 0.000 description 2
HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
238000010600 3H thymidine incorporation assay Methods 0.000 description 2
102000005666 Apolipoprotein A-I Human genes 0.000 description 2
108010059886 Apolipoprotein A-I Proteins 0.000 description 2
ILJQISGMGXRZQQ-IHRRRGAJSA-N Asp-Arg-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ILJQISGMGXRZQQ-IHRRRGAJSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 2
108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 2
102000000844 Cell Surface Receptors Human genes 0.000 description 2
108010001857 Cell Surface Receptors Proteins 0.000 description 2
238000012286 ELISA Assay Methods 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
206010055690 Foetal death Diseases 0.000 description 2
101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 2
102000008070 Interferon-gamma Human genes 0.000 description 2
108010002352 Interleukin-1 Proteins 0.000 description 2
108010002616 Interleukin-5 Proteins 0.000 description 2
102000000743 Interleukin-5 Human genes 0.000 description 2
108090001007 Interleukin-8 Proteins 0.000 description 2
102000004890 Interleukin-8 Human genes 0.000 description 2
102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 2
102100027180 Microtubule-associated protein 1A Human genes 0.000 description 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
108010003541 Platelet Activating Factor Proteins 0.000 description 2
WOUIMBGNEUWXQG-VKHMYHEASA-N Ser-Gly Chemical compound OC[C@H](N)C(=O)NCC(O)=O WOUIMBGNEUWXQG-VKHMYHEASA-N 0.000 description 2
SQHKXWODKJDZRC-LKXGYXEUSA-N Ser-Thr-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O SQHKXWODKJDZRC-LKXGYXEUSA-N 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
102100033598 Triosephosphate isomerase Human genes 0.000 description 2
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
241000700605 Viruses Species 0.000 description 2
230000009471 action Effects 0.000 description 2
230000001919 adrenal effect Effects 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
125000003545 alkoxy group Chemical group 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
230000003042 antagnostic effect Effects 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
230000007969 cellular immunity Effects 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
230000000056 copulatory effect Effects 0.000 description 2
210000004246 corpus luteum Anatomy 0.000 description 2
230000000875 corresponding effect Effects 0.000 description 2
238000012258 culturing Methods 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
108010046025 early pregnancy factor Proteins 0.000 description 2
210000000981 epithelium Anatomy 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
125000000623 heterocyclic group Chemical group 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
230000003053 immunization Effects 0.000 description 2
238000002649 immunization Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
208000021267 infertility disease Diseases 0.000 description 2
229960003130 interferon gamma Drugs 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
206010025135 lupus erythematosus Diseases 0.000 description 2
238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
108010005942 methionylglycine Proteins 0.000 description 2
210000004080 milk Anatomy 0.000 description 2
239000008267 milk Substances 0.000 description 2
235000013336 milk Nutrition 0.000 description 2
239000002159 nanocrystal Substances 0.000 description 2
210000001672 ovary Anatomy 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
239000000186 progesterone Substances 0.000 description 2
229960003387 progesterone Drugs 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
238000011084 recovery Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
210000003296 saliva Anatomy 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
210000004988 splenocyte Anatomy 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
210000002536 stromal cell Anatomy 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
230000003390 teratogenic effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
210000001685 thyroid gland Anatomy 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
230000001573 trophoblastic effect Effects 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
210000001215 vagina Anatomy 0.000 description 2
230000000007 visual effect Effects 0.000 description 2
125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
102100029444 28S ribosomal protein S10, mitochondrial Human genes 0.000 description 1
125000003341 7 membered heterocyclic group Chemical group 0.000 description 1
102100029325 ATP-dependent DNA helicase PIF1 Human genes 0.000 description 1
NCQMBSJGJMYKCK-ZLUOBGJFSA-N Ala-Ser-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O NCQMBSJGJMYKCK-ZLUOBGJFSA-N 0.000 description 1
WQKAQKZRDIZYNV-VZFHVOOUSA-N Ala-Ser-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WQKAQKZRDIZYNV-VZFHVOOUSA-N 0.000 description 1
LIWMQSWFLXEGMA-WDSKDSINSA-N Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)N LIWMQSWFLXEGMA-WDSKDSINSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
101100288313 Arabidopsis thaliana KTI4 gene Proteins 0.000 description 1
KXOPYFNQLVUOAQ-FXQIFTODSA-N Arg-Ser-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O KXOPYFNQLVUOAQ-FXQIFTODSA-N 0.000 description 1
241001312218 Arisaema triphyllum Species 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
GIQCDTKOIPUDSG-GARJFASQSA-N Asn-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)N)C(=O)O GIQCDTKOIPUDSG-GARJFASQSA-N 0.000 description 1
COWITDLVHMZSIW-CIUDSAMLSA-N Asn-Lys-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O COWITDLVHMZSIW-CIUDSAMLSA-N 0.000 description 1
FAUPLTGRUBTXNU-FXQIFTODSA-N Asp-Pro-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O FAUPLTGRUBTXNU-FXQIFTODSA-N 0.000 description 1
101001125884 Autographa californica nuclear polyhedrosis virus Per os infectivity factor 1 Proteins 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
101000839068 Boana punctata Hylaseptin-P1 Proteins 0.000 description 1
238000011740 C57BL/6 mouse Methods 0.000 description 1
101100512078 Caenorhabditis elegans lys-1 gene Proteins 0.000 description 1
101100505161 Caenorhabditis elegans mel-32 gene Proteins 0.000 description 1
GXGJIOMUZAGVEH-UHFFFAOYSA-N Chamazulene Chemical group CCC1=CC=C(C)C2=CC=C(C)C2=C1 GXGJIOMUZAGVEH-UHFFFAOYSA-N 0.000 description 1
102000008169 Co-Repressor Proteins Human genes 0.000 description 1
108010060434 Co-Repressor Proteins Proteins 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
235000006481 Colocasia esculenta Nutrition 0.000 description 1
206010061452 Complication of pregnancy Diseases 0.000 description 1
102100039077 Cytosolic 10-formyltetrahydrofolate dehydrogenase Human genes 0.000 description 1
150000008574 D-amino acids Chemical class 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
206010052804 Drug tolerance Diseases 0.000 description 1
238000008157 ELISA kit Methods 0.000 description 1
102100025137 Early activation antigen CD69 Human genes 0.000 description 1
102100031804 Electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial Human genes 0.000 description 1
108010069915 Electron-transferring-flavoprotein dehydrogenase Proteins 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241001331845 Equus asinus x caballus Species 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
KIEICAOUSNYOLM-NRPADANISA-N Glu-Val-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O KIEICAOUSNYOLM-NRPADANISA-N 0.000 description 1
WKJKBELXHCTHIJ-WPRPVWTQSA-N Gly-Arg-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N WKJKBELXHCTHIJ-WPRPVWTQSA-N 0.000 description 1
BBTCXWTXOXUNFX-IUCAKERBSA-N Gly-Met-Arg Chemical compound CSCC[C@H](NC(=O)CN)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O BBTCXWTXOXUNFX-IUCAKERBSA-N 0.000 description 1
BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 1
102000006771 Gonadotropins Human genes 0.000 description 1
108010086677 Gonadotropins Proteins 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
102100039165 Heat shock protein beta-1 Human genes 0.000 description 1
101710100504 Heat shock protein beta-1 Proteins 0.000 description 1
102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
KRBMQYPTDYSENE-BQBZGAKWSA-N His-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CNC=N1 KRBMQYPTDYSENE-BQBZGAKWSA-N 0.000 description 1
101000699882 Homo sapiens 28S ribosomal protein S10, mitochondrial Proteins 0.000 description 1
101001125842 Homo sapiens ATP-dependent DNA helicase PIF1 Proteins 0.000 description 1
101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
101001057324 Homo sapiens Microtubule-associated protein 1A Proteins 0.000 description 1
101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
150000008575 L-amino acids Chemical class 0.000 description 1
208000035752 Live birth Diseases 0.000 description 1
RQILLQOQXLZTCK-KBPBESRZSA-N Lys-Tyr-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O RQILLQOQXLZTCK-KBPBESRZSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
ACYHZNZHIZWLQF-BQBZGAKWSA-N Met-Asn-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O ACYHZNZHIZWLQF-BQBZGAKWSA-N 0.000 description 1
CAODKDAPYGUMLK-FXQIFTODSA-N Met-Asn-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O CAODKDAPYGUMLK-FXQIFTODSA-N 0.000 description 1
WXXNVZMWHOLNRJ-AVGNSLFASA-N Met-Pro-Lys Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O WXXNVZMWHOLNRJ-AVGNSLFASA-N 0.000 description 1
108050006673 Microtubule associated protein 1A Proteins 0.000 description 1
102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
230000006051 NK cell activation Effects 0.000 description 1
206010067482 No adverse event Diseases 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
206010036595 Premature delivery Diseases 0.000 description 1
239000004365 Protease Substances 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
102000004394 Ribosomal protein S10 Human genes 0.000 description 1
108090000928 Ribosomal protein S10 Proteins 0.000 description 1
PQEQXWRVHQAAKS-SRVKXCTJSA-N Ser-Tyr-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)N)CC1=CC=C(O)C=C1 PQEQXWRVHQAAKS-SRVKXCTJSA-N 0.000 description 1
241000282887 Suidae Species 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
101150033985 TPI gene Proteins 0.000 description 1
101150032817 TPI1 gene Proteins 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
108700015934 Triose-phosphate isomerases Proteins 0.000 description 1
101710194411 Triosephosphate isomerase 1 Proteins 0.000 description 1
LAYSXAOGWHKNED-XPUUQOCRSA-N Val-Gly-Ser Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O LAYSXAOGWHKNED-XPUUQOCRSA-N 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
210000000683 abdominal cavity Anatomy 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000004308 accommodation Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
125000003368 amide group Chemical group 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000007503 antigenic stimulation Effects 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
108010013835 arginine glutamate Proteins 0.000 description 1
238000003491 array Methods 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
238000011948 assay development Methods 0.000 description 1
230000003305 autocrine Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
239000012472 biological sample Substances 0.000 description 1
239000000090 biomarker Substances 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
238000007413 biotinylation Methods 0.000 description 1
230000006287 biotinylation Effects 0.000 description 1
230000029803 blastocyst development Effects 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
208000015294 blood coagulation disease Diseases 0.000 description 1
230000037396 body weight Effects 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
230000001364 causal effect Effects 0.000 description 1
230000032823 cell division Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
210000004081 cilia Anatomy 0.000 description 1
230000004087 circulation Effects 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000010367 cloning Methods 0.000 description 1
230000009852 coagulant defect Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
239000000562 conjugate Substances 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
229940124558 contraceptive agent Drugs 0.000 description 1
238000012937 correction Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
210000004292 cytoskeleton Anatomy 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007123 defense Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
230000013020 embryo development Effects 0.000 description 1
210000002308 embryonic cell Anatomy 0.000 description 1
230000009088 enzymatic function Effects 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
230000035558 fertility Effects 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
230000008217 follicular development Effects 0.000 description 1
210000001733 follicular fluid Anatomy 0.000 description 1
238000009472 formulation Methods 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
125000003838 furazanyl group Chemical group 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
230000004927 fusion Effects 0.000 description 1
108010051015 glutathione-independent formaldehyde dehydrogenase Proteins 0.000 description 1
239000002622 gonadotropin Substances 0.000 description 1
230000036449 good health Effects 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
230000012447 hatching Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
230000002607 hemopoietic effect Effects 0.000 description 1
108010018006 histidylserine Proteins 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
230000004727 humoral immunity Effects 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
125000002632 imidazolidinyl group Chemical group 0.000 description 1
125000002636 imidazolinyl group Chemical group 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
230000036737 immune function Effects 0.000 description 1
230000008073 immune recognition Effects 0.000 description 1
238000003365 immunocytochemistry Methods 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000002055 immunohistochemical effect Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
208000000509 infertility Diseases 0.000 description 1
230000036512 infertility Effects 0.000 description 1
231100000535 infertility Toxicity 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000009027 insemination Effects 0.000 description 1
230000008316 intracellular mechanism Effects 0.000 description 1
238000010212 intracellular staining Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000003446 ligand Substances 0.000 description 1
239000002502 liposome Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000007108 local immune response Effects 0.000 description 1
230000004807 localization Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
108010003700 lysyl aspartic acid Proteins 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
238000002493 microarray Methods 0.000 description 1
108010041420 microbial alkaline proteinase inhibitor Proteins 0.000 description 1
230000001617 migratory effect Effects 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
230000002438 mitochondrial effect Effects 0.000 description 1
230000002297 mitogenic effect Effects 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
108091005601 modified peptides Proteins 0.000 description 1
230000000051 modifying effect Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
125000002757 morpholinyl group Chemical group 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
210000000287 oocyte Anatomy 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000035515 penetration Effects 0.000 description 1
239000000863 peptide conjugate Substances 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
230000003836 peripheral circulation Effects 0.000 description 1
230000035699 permeability Effects 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000005936 piperidyl group Chemical group 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
208000012113 pregnancy disease Diseases 0.000 description 1
230000037452 priming Effects 0.000 description 1
230000007112 pro inflammatory response Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
150000003147 proline derivatives Chemical class 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
230000004850 protein–protein interaction Effects 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000003072 pyrazolidinyl group Chemical group 0.000 description 1
125000002755 pyrazolinyl group Chemical group 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
125000000719 pyrrolidinyl group Chemical group 0.000 description 1
125000001422 pyrrolinyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
229930002330 retinoic acid Natural products 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000007017 scission Effects 0.000 description 1
108010071207 serylmethionine Proteins 0.000 description 1
229940126586 small molecule drug Drugs 0.000 description 1
229940036051 sojourn Drugs 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
108010004034 stable plasma protein solution Proteins 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
238000006277 sulfonation reaction Methods 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000001839 systemic circulation Effects 0.000 description 1
125000001113 thiadiazolyl group Chemical group 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
150000007970 thio esters Chemical class 0.000 description 1
125000005505 thiomorpholino group Chemical group 0.000 description 1
125000004568 thiomorpholinyl group Chemical group 0.000 description 1
108010061238 threonyl-glycine Proteins 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000014616 translation Effects 0.000 description 1
229960001727 tretinoin Drugs 0.000 description 1
125000001425 triazolyl group Chemical group 0.000 description 1
210000000251 trophoblastic cell Anatomy 0.000 description 1
210000003954 umbilical cord Anatomy 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
230000036642 wellbeing Effects 0.000 description 1
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
229960001600 xylazine Drugs 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
- G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/367—Infertility, e.g. sperm disorder, ovulatory dysfunction
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Urology & Nephrology (AREA)
Biochemistry (AREA)
Pharmacology & Pharmacy (AREA)
Biotechnology (AREA)
Reproductive Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pathology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Microbiology (AREA)
Toxicology (AREA)
Zoology (AREA)
Rheumatology (AREA)
Rehabilitation Therapy (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Endocrinology (AREA)
Genetics & Genomics (AREA)
Gynecology & Obstetrics (AREA)

IL175063A 2003-10-22 2006-04-20 Use of pif peptides in the manufacture of a medicament for treating intolerance to embryo implantation IL175063A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US51337003P	2003-10-22	2003-10-22
US48224403A	2003-12-22	2003-12-22
PCT/US2004/035382 WO2005040196A2 (fr)	2003-10-22	2004-10-22	Activites biologiques de peptides pif, site d'action, et anticorps pour detecter pif

Publications (2)

Publication Number	Publication Date
IL175063A0 IL175063A0 (en)	2006-08-20
IL175063A true IL175063A (en)	2011-10-31

Family

ID=34526220

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL175063A IL175063A (en)	2003-10-22	2006-04-20	Use of pif peptides in the manufacture of a medicament for treating intolerance to embryo implantation

Country Status (5)

Country	Link
AU (1)	AU2004284097B2 (fr)
CA (1)	CA2584690C (fr)
IL (1)	IL175063A (fr)
NZ (1)	NZ547139A (fr)
WO (1)	WO2005040196A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8222211B2 (en)	2001-07-02	2012-07-17	Bioincept, Llc	Methods of administering PIF agonist peptides and uses thereof
US7273708B2 (en)	2001-07-02	2007-09-25	Bioincept, Llc	Assays for preimplantation factor and preimplantation factor peptides
US7723289B2 (en) *	2003-10-22	2010-05-25	Bioincept, Llc	PIF tetrapeptides
US7723290B2 (en)	2004-10-22	2010-05-25	Bioincept, Llc	Compositions and methods for modulating the immune system
US9737585B2 (en)	2011-03-02	2017-08-22	Bioincept, Llc	Compositions and methods for treatment of intracellular damage and bacterial infection
WO2017039751A1 (fr)	2015-08-28	2017-03-09	Bioincept, Llc	Peptides mutants et procédés de traitement de sujets les employant
EP2970496B1 (fr)	2013-03-12	2018-07-18	Institute of Arthritis Research LLC	Polypeptide actif d'un point de vue immunologique
EP3060924B1 (fr) *	2013-10-22	2022-06-01	Bioincept LLC	Cellules transfectées par un pif et procédés d'utilisation
US20170336406A1 (en) *	2014-09-16	2017-11-23	Bioincept, Llc	Pif binding as a marker for immune dysregulation
JP6806685B2 (ja) *	2014-09-16	2021-01-06	バイオインセプト、エルエルシー	急性放射線症候群を治療するための組成物及び方法
EP3341006A4 (fr)	2015-08-28	2019-03-13	BioIncept LLC	Compositions et méthodes pour le traitement d'une lésion neurologique
US20240293501A1 (en) *	2020-06-18	2024-09-05	Michael J. Paidas	Reagents, Pharmaceutical Formulations, and Methods for Treating and Preventing Viral Infection

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7273708B2 (en)	2001-07-02	2007-09-25	Bioincept, Llc	Assays for preimplantation factor and preimplantation factor peptides
WO2004053086A2 (fr) *	2002-12-06	2004-06-24	Epimmune, Inc.	Antigenes de plasmodium falciparum et procedes d'utilisation

2004
- 2004-10-22 WO PCT/US2004/035382 patent/WO2005040196A2/fr not_active Ceased
- 2004-10-22 NZ NZ547139A patent/NZ547139A/en not_active IP Right Cessation
- 2004-10-22 CA CA2584690A patent/CA2584690C/fr not_active Expired - Fee Related
- 2004-10-22 AU AU2004284097A patent/AU2004284097B2/en not_active Ceased
2006
- 2006-04-20 IL IL175063A patent/IL175063A/en active IP Right Grant

Also Published As

Publication number	Publication date
AU2004284097B2 (en)	2011-05-12
AU2004284097A1 (en)	2005-05-06
IL175063A0 (en)	2006-08-20
CA2584690C (fr)	2015-10-06
WO2005040196A3 (fr)	2006-08-17
NZ547139A (en)	2009-12-24
CA2584690A1 (fr)	2005-05-06
WO2005040196A2 (fr)	2005-05-06

Legal Events

Date	Code	Title
2012-02-29	FF	Patent granted
2014-10-30	KB	Patent renewed
2018-10-31	KB	Patent renewed

Publication	Publication Date	Title
CA3167498A1 (fr)	2021-08-19	Groupes d'epitopes de lymphocytes t et compositions associees utiles dans la prevention, le diagnostic et le traitement de la covid-19
US11000566B2 (en)	2021-05-11	Compositions and methods for modulating the immune system
WO2020082130A1 (fr)	2020-04-30	Récepteurs de lymphocytes t et utilisations associées
Gregerson et al.	1990	Identification of a potent new pathogenic site in human retinal S-antigen which induces experimental autoimmune uveoretinitis in LEW rats
AU2004284097B2 (en)	2011-05-12	PIF peptides biologic activities, site of action, and the antibody to detect PIF
EP1879604B1 (fr)	2020-06-03	Tetrapeptides pif
US8222211B2 (en)	2012-07-17	Methods of administering PIF agonist peptides and uses thereof
AU2019203459A1 (en)	2019-06-06	PIF binding as a marker for immune dysregulation
CN100339388C (zh)	2007-09-26	用于植入前因子的新型检测方法以及植入前因子肽
WO2009052415A1 (fr)	2009-04-23	Peptide destiné à l'induction d'une tolérance immunitaire en tant que traitement pour le lupus érythémateux systémique
CA2894868C (fr)	2017-12-12	Activites biologiques de peptides pif, site d'action, et anticorps pour detecter pif
Veaute et al.	2009	Acrosin antibodies and infertility. I. Detection of antibodies towards proacrosin/acrosin in women consulting for infertility and evaluation of their effects upon the sperm protease activities
EP1680442B1 (fr)	2011-07-13	Activites biologiques de peptides pif
WO2024249408A1 (fr)	2024-12-05	Auto-anticorps en tant que marqueurs de naissance prématurée
Kamada et al.	2001	Specific cytotoxicity of antibody to YAL-198, a sperm antigen peptide, to murine zygote
Zenclussen et al.	2002	Increased expression of chemokine receptor 5 (CCR5) in blood and decidual cells in a mouse model for preeclampsia (PE)
Jonáková et al.	2002	Mutual interactions of boar seminal plasma proteins studied by immunological and chromatographic methods
Fernekorn et al.	2002	Regulation of leukocyte recruitment to the murine maternal/fetal interface by specialized patterns of vascular adhesion receptors
Uthoff et al.	2002	The impact of maternal allergic sensitization on the development of pre‐and postnatal immunity
Fitzgerald et al.	2002	Is Stat3 activation in trophoblast cells required for invasiveness?
CN101024089A (zh)	2007-08-29	E4bp4基因在胚胎着床过程中的功能及其应用
Jerzak et al.	2002	Extracellular matrix proteins dependent apoptosis of T Cells in women with a history of recurrent spontaneous abortion
Madar et al.	2002	Antitrophoblast cell‐mediated immunity and anticardiolipin autoantibodies in repeatedly aborting women
Chaouat et al.	2008	Cytokine expression at interface: a longitudinal micro array